Clinical Trial Update: Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ex-vivo depletion of myeloma cells from peripheral blood progenitor cell grafts in multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN